Regeneron Pharmaceuticals, Inc.
Marktkapitalisierung
$81.5B
Globaler Rang
#193
Allzeithoch
$89.7B
2023-12-31
Gesamtwachstum
+0%
seit 2026
Market Cap Context
- Larger than 47% of the 367 companies we track (globally).
- Equivalent to 0.3% of United States's GDP (2025 data).
- Just above: #192 Illinois Tool Works Inc. ($81.8B)
- Just below: #194 Industrial and Commercial Bank of China Limited ($81.5B)
- Best year: 1995 (+325%). Worst year: 1997 (-47%).
Regeneron Pharmaceuticals, Inc. Financial Breakdown (FY 2025)
Source: Yahoo Finance — REGN annual filings (2025) →$14.3B revenue · $3.7B operating income · $4.5B net income
- ●Operating margin: 25.8% on $14.3B in revenue.
- ●R&D is 40.8% of revenue ($5.9B).
- ●Net income margin: 31.4% — $4.5B in profit.
- ●Free cash flow: $3.8B (26.3% of revenue).
Cost / Operating Expenses
Total operating expenses $10.6B
Total
$10.7B
Capital Expenditures
$1.2B
This fiscal year (near-total AI infrastructure buildout)
Free Cash Flow
$3.8B
Trailing twelve months
Figures rounded from the annual SEC filing. Unaudited. For informational purposes only, not investment advice.
Über Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Verlauf der Marktkapitalisierung von Regeneron Pharmaceuticals, Inc. (2026–2026)
Regeneron Pharmaceuticals, Inc. vs Sector Peers by Market Cap
Regeneron Pharmaceuticals, Inc. vergleichen
Rangverlauf
| Jahr | Marktkapitalisierung | Rang | Veränderung ggü. Vorjahr |
|---|---|---|---|
| 2026 | $81.5B | #193(↓13) | +2.8% |
| 2025 | $79.3B | #180(↓8) | +9.0% |
| 2024 | $72.8B | #172(↓46) | -18.9% |
| 2023 | $89.7B | #126(↓3) | +21.7% |
| 2022 | $73.7B | #123(↑27) | +14.2% |
| 2021 | $64.5B | #150(↑24) | +30.7% |
| 2020 | $49.4B | #174(↑11) | +28.7% |
| 2019 | $38.4B | #185(↓45) | +0.5% |
| 2018 | $38.2B | #140(↑9) | -0.7% |
| 2017 | $38.4B | #149(↓24) | +2.4% |
| 2016 | $37.5B | #125(↓58) | -32.4% |
| 2015 | $55.5B | #67(↑23) | +32.3% |
| 2014 | $41.9B | #90(↑35) | +49.1% |
| 2013 | $28.1B | #125(↑20) | +60.9% |
| 2012 | $17.5B | #145(↑94) | +208.6% |
| 2011 | $5.7B | #239(↑27) | +68.8% |
| 2010 | $3.4B | #266(↓2) | +35.8% |
| 2009 | $2.5B | #264(↓8) | +31.7% |
| 2008 | $1.9B | #256(↑6) | -24.0% |
| 2007 | $2.5B | #262(↓6) | +20.3% |
| 2006 | $2.1B | #256 | +26.2% |
| 2005 | $1.6B | #256(↓4) | +72.6% |
| 2004 | $941.1M | #252(↓15) | -37.4% |
| 2003 | $1.5B | #237(↓27) | -20.5% |
| 2002 | $1.9B | #210(↓12) | -34.3% |
| 2001 | $2.9B | #198(↓25) | -20.1% |
| 2000 | $3.6B | #173 | +176.6% |
| 1999 | $1.3B | #173 | +72.9% |
| 1998 | $753.6M | #173(↓10) | -13.9% |
| 1997 | $874.9M | #163(↓37) | -46.9% |
| 1996 | $1.6B | #126(↓6) | +26.5% |
| 1995 | $1.3B | #120(↑13) | +325.0% |
| 1994 | $306.5M | #133 |
Weitere Unternehmen im Sektor Gesundheitswesen
FAQ
What is Regeneron Pharmaceuticals, Inc.'s market cap?
Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalization of $81.5B, making it the #193 largest company in the world by market cap.
What was Regeneron Pharmaceuticals, Inc.'s highest market cap?
Regeneron Pharmaceuticals, Inc.'s all-time high market cap was $89.7B, reached in 2023-12-31. Its highest rank was #126 in 2023.
What sector is Regeneron Pharmaceuticals, Inc. in?
Regeneron Pharmaceuticals, Inc. is in the Healthcare sector, specifically the Biotechnology industry. It is based in United States.
How has Regeneron Pharmaceuticals, Inc.'s market cap changed over time?
Regeneron Pharmaceuticals, Inc. has been tracked since 2026. Its market cap has grown by 0% from $81.5B in 2026 to $81.5B today.